Pub Date : 2025-09-17DOI: 10.1016/j.bulcan.2025.07.012
Guangxu Wang , Xiaoming Sun , Qiaoling Liu , Zhanyue Pang , Yubin Huang , Lin Lv , Houlu Zhang , Haibo Liu , Liangming Zhu
Background
Mitochondrial dysfunction and metabolic reprogramming contribute to the occurrence and progression of esophageal squamous cell carcinoma (ESCC). Several studies confirmed the involvement of mitochondrial ribosomal protein L12 (MRPL12) in regulating mitochondrial metabolism. Mitochondrial ribosomal protein L7/L12 (MRPL12) is a gene that regulates mitochondrial transcription. However, its role in esophageal tumorigenesis remains unknown.
Methods
MRPL12 expression in ESCC and its transcription factors were assessed by Online databases. Its expression in ESCC tissues from oesophageal cancer patients, patient-derived ESCC tissues, and cell lines was detected by western blotting, RT-qPCR and immunohistochemistry. A series of cellular experiments, including gene knockout and overexpression were performed in esophageal cancer cell lines. Scratch assay, Transwell assay and CCK-8 cell viability assay were performed to establish the proliferation and migration of esophageal cancer cell lines.
Results
A significant MRPL12 upregulation was observed in ESCC cells and tissues. MRPL12 overexpression promoted cell proliferation, migration, and invasion in vitro, while MRPL12 knockout induced the opposite effect. Subsequently, the most relevant transcription factors ZNF460 and ZNF135 for MRPL12 were found by online databases.
Conclusion
A new role of MRPL12 in ESCC was discovered. MRPL12 represented a potential prognostic biomarker for ESCC, and the reduction in MRPL12 expression might be a potential therapeutic approach to inhibit ESCC progression.
{"title":"High MRPL12 expression drives esophageal cancer proliferation, invasion and migration","authors":"Guangxu Wang , Xiaoming Sun , Qiaoling Liu , Zhanyue Pang , Yubin Huang , Lin Lv , Houlu Zhang , Haibo Liu , Liangming Zhu","doi":"10.1016/j.bulcan.2025.07.012","DOIUrl":"10.1016/j.bulcan.2025.07.012","url":null,"abstract":"<div><h3>Background</h3><div>Mitochondrial dysfunction and metabolic reprogramming contribute to the occurrence and progression of esophageal squamous cell carcinoma (ESCC). Several studies confirmed the involvement of mitochondrial ribosomal protein L12 (MRPL12) in regulating mitochondrial metabolism. Mitochondrial ribosomal protein L7/L12 (MRPL12) is a gene that regulates mitochondrial transcription. However, its role in esophageal tumorigenesis remains unknown.</div></div><div><h3>Methods</h3><div>MRPL12 expression in ESCC and its transcription factors were assessed by Online databases. Its expression in ESCC tissues from oesophageal cancer patients, patient-derived ESCC tissues, and cell lines was detected by western blotting, RT-qPCR and immunohistochemistry. A series of cellular experiments, including gene knockout and overexpression were performed in esophageal cancer cell lines. Scratch assay, Transwell assay and CCK-8 cell viability assay were performed to establish the proliferation and migration of esophageal cancer cell lines.</div></div><div><h3>Results</h3><div>A significant MRPL12 upregulation was observed in ESCC cells and tissues. MRPL12 overexpression promoted cell proliferation, migration, and invasion <em>in vitro</em>, while MRPL12 knockout induced the opposite effect. Subsequently, the most relevant transcription factors ZNF460 and ZNF135 for MRPL12 were found by online databases.</div></div><div><h3>Conclusion</h3><div>A new role of MRPL12 in ESCC was discovered. MRPL12 represented a potential prognostic biomarker for ESCC, and the reduction in MRPL12 expression might be a potential therapeutic approach to inhibit ESCC progression.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 11","pages":"Pages 1240-1250"},"PeriodicalIF":0.8,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145088506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-17DOI: 10.1016/j.bulcan.2025.07.022
Lydia Cherfaoui, Michael Loschi
{"title":"Ruxolitinib – GvHD aiguë ou chronique après échec d’une corticothérapie","authors":"Lydia Cherfaoui, Michael Loschi","doi":"10.1016/j.bulcan.2025.07.022","DOIUrl":"10.1016/j.bulcan.2025.07.022","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 11","pages":"Pages 1234-1235"},"PeriodicalIF":0.8,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145088567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-17DOI: 10.1016/j.bulcan.2025.07.023
Camille Malbrun, Maud D’Aveni
{"title":"Imetelstat dans le syndrome myélodysplasique de risque faible ou intermédiaire sans délétion 5q chez les patients présentant une dépendance transfusionnelle","authors":"Camille Malbrun, Maud D’Aveni","doi":"10.1016/j.bulcan.2025.07.023","DOIUrl":"10.1016/j.bulcan.2025.07.023","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 11","pages":"Pages 1232-1234"},"PeriodicalIF":0.8,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145088516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-15DOI: 10.1016/j.bulcan.2025.07.020
Alexandre Quillet , Nasreddine Khadraoui , Nicolas Isambert , Thomas Systchenko , Nolwenn Le Stang , Gautier Defossez
Background
Lung cancer remains a global public health challenge, with late-stage diagnosis limiting treatment options. Surgery is recommended for early-stage disease (I-IIIA) and can only be performed in authorized centres. The aim of this study is to provide a spatial description of access to surgery for lung cancer patients and to identify the sociodemographic characteristics of patients who are furthest from home for their treatment.
Methods
A population-based study was conducted on patients diagnosed with non-small cell lung cancer (stages I-IIIA) between 2008 and 2020, identified from the Poitou-Charentes Cancer Registry (south-western France). The distance between the patient's home and the place of surgery was computed using geographic coordinates. A map of patient flows by department was produced. Logistic regression models were used to identify sociodemographic and tumour factors associated with distance to surgery (cut-off 100 km). Sensitivity analyses were performed by varying the distance threshold (50, 150 and 200 km).
Results
Twenty-two percent of patients travelled more than 100 km for surgery. This proportion was higher in Charente and Charente-Maritime (45% and 31% respectively) than in Deux-Sèvres and Vienne (9% and 2% respectively). Female sex and middle socioeconomic status were associated with a greater distance travelled for surgery. Sex was the only variable that remained significant for all thresholds studied.
Conclusions
Sociodemographic factors including sex, place of residence and socioeconomic status are important determinants of distance travelled for lung cancer surgery. These findings allow better understanding of these patients’ pathways taking into account regional specificities.
{"title":"What are the sociodemographic characteristics of lung cancer patients travelling far to get surgery?","authors":"Alexandre Quillet , Nasreddine Khadraoui , Nicolas Isambert , Thomas Systchenko , Nolwenn Le Stang , Gautier Defossez","doi":"10.1016/j.bulcan.2025.07.020","DOIUrl":"10.1016/j.bulcan.2025.07.020","url":null,"abstract":"<div><h3>Background</h3><div>Lung cancer remains a global public health challenge, with late-stage diagnosis limiting treatment options. Surgery is recommended for early-stage disease (I-IIIA) and can only be performed in authorized centres. The aim of this study is to provide a spatial description of access to surgery for lung cancer patients and to identify the sociodemographic characteristics of patients who are furthest from home for their treatment.</div></div><div><h3>Methods</h3><div>A population-based study was conducted on patients diagnosed with non-small cell lung cancer (stages I-IIIA) between 2008 and 2020, identified from the Poitou-Charentes Cancer Registry (south-western France). The distance between the patient's home and the place of surgery was computed using geographic coordinates. A map of patient flows by department was produced. Logistic regression models were used to identify sociodemographic and tumour factors associated with distance to surgery (cut-off 100<!--> <!-->km). Sensitivity analyses were performed by varying the distance threshold (50, 150 and 200<!--> <!-->km).</div></div><div><h3>Results</h3><div>Twenty-two percent of patients travelled more than 100<!--> <!-->km for surgery. This proportion was higher in Charente and Charente-Maritime (45% and 31% respectively) than in Deux-Sèvres and Vienne (9% and 2% respectively). Female sex and middle socioeconomic status were associated with a greater distance travelled for surgery. Sex was the only variable that remained significant for all thresholds studied.</div></div><div><h3>Conclusions</h3><div>Sociodemographic factors including sex, place of residence and socioeconomic status are important determinants of distance travelled for lung cancer surgery. These findings allow better understanding of these patients’ pathways taking into account regional specificities.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 11","pages":"Pages 1293-1300"},"PeriodicalIF":0.8,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145076879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-12DOI: 10.1016/j.bulcan.2024.12.019
François-Régis Ferrand
{"title":"Complications otologiques au cours de la prise en charge des cancers : éditorial","authors":"François-Régis Ferrand","doi":"10.1016/j.bulcan.2024.12.019","DOIUrl":"10.1016/j.bulcan.2024.12.019","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 10","pages":"Pages 1075-1077"},"PeriodicalIF":0.8,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-12DOI: 10.1016/j.bulcan.2025.07.008
Joe El Khoury , Nathalie Guillet , Camille Boccaccini
{"title":"Des images choisies, des liens tissés : Horizons Suspendus, ou quand l’environnement devient soin","authors":"Joe El Khoury , Nathalie Guillet , Camille Boccaccini","doi":"10.1016/j.bulcan.2025.07.008","DOIUrl":"10.1016/j.bulcan.2025.07.008","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 10","pages":"Pages 1087-1091"},"PeriodicalIF":0.8,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-12DOI: 10.1016/j.bulcan.2025.07.009
Mathilde Haberstich , Manuel Rodrigues
{"title":"Pembrolizumab en association avec radiochimiothérapie dans les cancers du col localement avancé à haut risque","authors":"Mathilde Haberstich , Manuel Rodrigues","doi":"10.1016/j.bulcan.2025.07.009","DOIUrl":"10.1016/j.bulcan.2025.07.009","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 11","pages":"Pages 1231-1232"},"PeriodicalIF":0.8,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-11DOI: 10.1016/j.bulcan.2025.07.018
Sarah Mir , Katia Desroziers , Sarah Saget , Alexandre Gherardi , Amandine Groenez , Julie Paolantonacci , Anne-Cécile Regin , Béchir Ben Hadj Yahia , Cyril Esnault , Christos Chouaid
<div><h3>Introduction</h3><div>L’avènement de la voie d’administration sous-cutanée en oncologie a entraîné des modifications importantes dans la prise en charge des patients et pour les professionnels de santé avec des impacts organisationnels et économiques forts peu documentés. Cette revue de littérature pragmatique vise à identifier les différences entre les voies d’administration sous-cutanée et intraveineuse en oncologie pour les patients, professionnels de santé et établissements de santé, y compris les implications économiques associées.</div></div><div><h3>Méthodes</h3><div>L’analyse repose sur la méthodologie PRISMA pour identifier les articles et posters pertinents publiés ou présentés entre 2017 et septembre 2023 dans cinq pays européens à l’aide de mots clés relatifs à la perspective patients, aux impacts organisationnels pour les établissements et aux impacts économiques.</div></div><div><h3>Résultats</h3><div>Parmi les 558 articles et communications identifiés, seize répondaient aux critères d’inclusion et d’exclusion. Entre 69 et 99 % des patients indiquaient préférer la voie sous-cutanée, principalement pour le gain de temps permis. Le temps de séjour dans l’établissement était lui réduit de 33 à 68 % chez les patients sous trastuzumab. En France, l’optimisation des circuits de soins pour l’administration sous-cutanée de trastuzumab et de rituximab permettait un gain total potentiel moyen de 157 103 € par service.</div></div><div><h3>Discussion</h3><div>Cette revue de littérature souligne les avantages substantiels de l’utilisation de la voie sous-cutanée par rapport à la voie intraveineuse en oncologie. Son usage est nettement préféré par les patients et professionnels et permet des économies notables, accrues par la mise en place de circuits de soins dédiés.</div></div><div><h3>Introduction</h3><div>The introduction of subcutaneous formulation in oncology led to significant changes for patients and healthcare professionals, with under-explored organizational and economic impacts. The aim of this pragmatic literature review is to compile evidence documenting the impact of subcutaneous formulation in comparison with intravenous administration in oncology, on patients, healthcare professionals and health facilities, and the associated economic implications.</div></div><div><h3>Methods</h3><div>The analysis is based on the PRISMA methodology to identify relevant articles and posters published or presented between 2017 and September 2023 in five major European countries, using keywords related to patients perspective, organizational impacts on health facilities, and economic impacts.</div></div><div><h3>Results</h3><div>Among the 558 identified articles and communications, 16 met the inclusion and exclusion criteria. Between 69% and 99% of patients indicated a preference for the subcutaneous formulation mainly due to the timesaving benefits it allows. The duration of inpatient hospital stay was reduced by 33% to 68% for patients tre
{"title":"Voie sous-cutanée versus voie intraveineuse en oncologie : préférences et impacts pour les patients et professionnels de santé","authors":"Sarah Mir , Katia Desroziers , Sarah Saget , Alexandre Gherardi , Amandine Groenez , Julie Paolantonacci , Anne-Cécile Regin , Béchir Ben Hadj Yahia , Cyril Esnault , Christos Chouaid","doi":"10.1016/j.bulcan.2025.07.018","DOIUrl":"10.1016/j.bulcan.2025.07.018","url":null,"abstract":"<div><h3>Introduction</h3><div>L’avènement de la voie d’administration sous-cutanée en oncologie a entraîné des modifications importantes dans la prise en charge des patients et pour les professionnels de santé avec des impacts organisationnels et économiques forts peu documentés. Cette revue de littérature pragmatique vise à identifier les différences entre les voies d’administration sous-cutanée et intraveineuse en oncologie pour les patients, professionnels de santé et établissements de santé, y compris les implications économiques associées.</div></div><div><h3>Méthodes</h3><div>L’analyse repose sur la méthodologie PRISMA pour identifier les articles et posters pertinents publiés ou présentés entre 2017 et septembre 2023 dans cinq pays européens à l’aide de mots clés relatifs à la perspective patients, aux impacts organisationnels pour les établissements et aux impacts économiques.</div></div><div><h3>Résultats</h3><div>Parmi les 558 articles et communications identifiés, seize répondaient aux critères d’inclusion et d’exclusion. Entre 69 et 99 % des patients indiquaient préférer la voie sous-cutanée, principalement pour le gain de temps permis. Le temps de séjour dans l’établissement était lui réduit de 33 à 68 % chez les patients sous trastuzumab. En France, l’optimisation des circuits de soins pour l’administration sous-cutanée de trastuzumab et de rituximab permettait un gain total potentiel moyen de 157 103 € par service.</div></div><div><h3>Discussion</h3><div>Cette revue de littérature souligne les avantages substantiels de l’utilisation de la voie sous-cutanée par rapport à la voie intraveineuse en oncologie. Son usage est nettement préféré par les patients et professionnels et permet des économies notables, accrues par la mise en place de circuits de soins dédiés.</div></div><div><h3>Introduction</h3><div>The introduction of subcutaneous formulation in oncology led to significant changes for patients and healthcare professionals, with under-explored organizational and economic impacts. The aim of this pragmatic literature review is to compile evidence documenting the impact of subcutaneous formulation in comparison with intravenous administration in oncology, on patients, healthcare professionals and health facilities, and the associated economic implications.</div></div><div><h3>Methods</h3><div>The analysis is based on the PRISMA methodology to identify relevant articles and posters published or presented between 2017 and September 2023 in five major European countries, using keywords related to patients perspective, organizational impacts on health facilities, and economic impacts.</div></div><div><h3>Results</h3><div>Among the 558 identified articles and communications, 16 met the inclusion and exclusion criteria. Between 69% and 99% of patients indicated a preference for the subcutaneous formulation mainly due to the timesaving benefits it allows. The duration of inpatient hospital stay was reduced by 33% to 68% for patients tre","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 12","pages":"Pages 1394-1405"},"PeriodicalIF":0.8,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145056464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-09DOI: 10.1016/j.bulcan.2025.07.019
Katia Mahiou
{"title":"Cancer du sein et transidentité : vers une oncologie plus inclusive","authors":"Katia Mahiou","doi":"10.1016/j.bulcan.2025.07.019","DOIUrl":"10.1016/j.bulcan.2025.07.019","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 10","pages":"Pages 1092-1094"},"PeriodicalIF":0.8,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<div><h3>Contexte</h3><div>La prévalence des cancers et des hémopathies est élevée et continue de croître. La gravité de ces pathologies invite à offrir au patient la possibilité d’une expression de ses valeurs, notamment concernant l’intensité thérapeutique et les modalités de prise en charge dont il souhaite bénéficier. Pourtant la prévalence des directives anticipées dans cette population reste faible. L’objectif de notre étude était d’évaluer la perception des directives anticipées par les oncologues et hématologues français et leur implication dans la promotion et l’usage de ces directives.</div></div><div><h3>Méthode</h3><div>Étude prospective, observationnelle, transversale à partir d’un questionnaire en ligne envoyé à la population d’intérêt.</div></div><div><h3>Résultats</h3><div>Quatre cent dix oncologues (50,1 %) et 318 hématologues (33,7 %) ont répondu au questionnaire. Au total, 65,9 % des oncologues et 68,9 % des hématologues étaient praticiens hospitaliers ou équivalents. Les directives anticipées étaient proposées systématiquement ou fréquemment par 38,4 et 30,7 % des oncologues et des hématologues. Les principales limites à l’évocation des directives anticipées étaient la crainte de créer de l’angoisse chez les patients (oncologues : 74,6 % et hématologues : 64,4 %) et le fait que la maladie soit stable (32,9 et 54,1 %). Les directives anticipées étaient perçues comme peu utiles, voire dangereuses pour 24,9 et 27,4 %. Enfin, 68,5 et 67,3 % considéraient que la personne de confiance pourrait être plus pertinente que les directives anticipées.</div></div><div><h3>Conclusions</h3><div>La majorité des hématologues et des oncologues considère que les directives anticipées peuvent être utiles, cependant seul un tiers des praticiens les évoquent régulièrement. Le principal motif d’évitement des discussions concernant les directives anticipées était la crainte de créer de l’anxiété.</div></div><div><h3>Background</h3><div>The prevalence of cancers and hematological malignancies is high and continues to grow. The severity of these pathologies calls for patients to be given the opportunity to express their values, particularly with regard to the intensity of treatment and the type of care they wish to receive. However, the prevalence of advance directives (ADs) in this population remains low. The aim of our study was to assess the perception of advance directives by French oncologists and hematologists, and their involvement in the promotion and use of these directives.</div></div><div><h3>Methods</h3><div>Observational, cross-sectional study based on an online questionnaire sent to the population of interest.</div></div><div><h3>Results</h3><div>Four hundred and ten oncologists (50.1%) and 318 haematologists (33.7%) completed the questionnaire. In total, 65.9% of oncologists and 68.9% of hematologists were attending physicians or equivalent. ADs were systematically or frequently offered to the patients by 38.4 and 30.7% of oncologists and
{"title":"Perception des directives anticipées en oncologie et hématologie : une étude nationale française auprès des cliniciens","authors":"Amélie Cambriel , Kevin Serey , Adrien Pollina-Bachellerie , Mathilde Cancel , Jacques-Olivier Bay , Carole Bouleuc , Jean-Pierre Lotz , Francois Philippart","doi":"10.1016/j.bulcan.2025.06.009","DOIUrl":"10.1016/j.bulcan.2025.06.009","url":null,"abstract":"<div><h3>Contexte</h3><div>La prévalence des cancers et des hémopathies est élevée et continue de croître. La gravité de ces pathologies invite à offrir au patient la possibilité d’une expression de ses valeurs, notamment concernant l’intensité thérapeutique et les modalités de prise en charge dont il souhaite bénéficier. Pourtant la prévalence des directives anticipées dans cette population reste faible. L’objectif de notre étude était d’évaluer la perception des directives anticipées par les oncologues et hématologues français et leur implication dans la promotion et l’usage de ces directives.</div></div><div><h3>Méthode</h3><div>Étude prospective, observationnelle, transversale à partir d’un questionnaire en ligne envoyé à la population d’intérêt.</div></div><div><h3>Résultats</h3><div>Quatre cent dix oncologues (50,1 %) et 318 hématologues (33,7 %) ont répondu au questionnaire. Au total, 65,9 % des oncologues et 68,9 % des hématologues étaient praticiens hospitaliers ou équivalents. Les directives anticipées étaient proposées systématiquement ou fréquemment par 38,4 et 30,7 % des oncologues et des hématologues. Les principales limites à l’évocation des directives anticipées étaient la crainte de créer de l’angoisse chez les patients (oncologues : 74,6 % et hématologues : 64,4 %) et le fait que la maladie soit stable (32,9 et 54,1 %). Les directives anticipées étaient perçues comme peu utiles, voire dangereuses pour 24,9 et 27,4 %. Enfin, 68,5 et 67,3 % considéraient que la personne de confiance pourrait être plus pertinente que les directives anticipées.</div></div><div><h3>Conclusions</h3><div>La majorité des hématologues et des oncologues considère que les directives anticipées peuvent être utiles, cependant seul un tiers des praticiens les évoquent régulièrement. Le principal motif d’évitement des discussions concernant les directives anticipées était la crainte de créer de l’anxiété.</div></div><div><h3>Background</h3><div>The prevalence of cancers and hematological malignancies is high and continues to grow. The severity of these pathologies calls for patients to be given the opportunity to express their values, particularly with regard to the intensity of treatment and the type of care they wish to receive. However, the prevalence of advance directives (ADs) in this population remains low. The aim of our study was to assess the perception of advance directives by French oncologists and hematologists, and their involvement in the promotion and use of these directives.</div></div><div><h3>Methods</h3><div>Observational, cross-sectional study based on an online questionnaire sent to the population of interest.</div></div><div><h3>Results</h3><div>Four hundred and ten oncologists (50.1%) and 318 haematologists (33.7%) completed the questionnaire. In total, 65.9% of oncologists and 68.9% of hematologists were attending physicians or equivalent. ADs were systematically or frequently offered to the patients by 38.4 and 30.7% of oncologists and","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 11","pages":"Pages 1257-1268"},"PeriodicalIF":0.8,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145031447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号